Isopentenylpyrophosphate

Isopentenylpyrophosphate

SCHEMBL1363821

C.C=C(C)CCOP(=O)(O)OP(=O)(O)O.C=C(C)CCOP(=O)(O)OP(=O)(O)O.C=C(C)CCOP(=O)(O)OP(=O)(O)O.C=C(C)CCOP(=O)(O)OP(=O)(O)O

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
BTN3A1 O00481 3/20 0.96
MVD P53602 2/20 0.44
FNTA P49354 5/20 0.41
PGGT1B P53609 3/20 0.41
FNTB P49356 3/20 0.41
GGPS1 O95749 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isopentenylpyrophosphate SCHEMBL125521 0.98 BTN3A1 (1.00) BTN3A1MVDFNTAPGGT1BFNTB
Isopentenylpyrophosphate SCHEMBL15053699 0.98 BTN3A1 (1.00) BTN3A1MVDFNTAPGGT1BFNTB
Isopentenylpyrophosphate SCHEMBL29787025 0.96 BTN3A1 (0.96) BTN3A1MVDFNTAPGGT1BFNTB
Isopentenylpyrophosphate SCHEMBL4363351 0.96 BTN3A1 (0.96) BTN3A1MVDFNTAPGGT1BFNTB
Isopentenylpyrophosphate SCHEMBL2027470 0.96 BTN3A1 (0.96) BTN3A1MVDFNTAPGGT1BFNTB
SCHEMBL3221121 0.94 BTN3A1 (0.93) BTN3A1MVDFNTAPGGT1BFNTB
Isopentenylpyrophosphate SCHEMBL21571357 0.94 BTN3A1 (0.93) BTN3A1MVDFNTAPGGT1BFNTB
Isopentenylpyrophosphate SCHEMBL21571270 0.91 BTN3A1 (0.86) BTN3A1MVDFNTAPGGT1BFNTB
SCHEMBL3211424 0.90 BTN3A1 (0.85) BTN3A1MVDFNTAPGGT1BFNTB
Isopentenylpyrophosphate SCHEMBL28764772 0.90 BTN3A1 (0.83) BTN3A1MVDFNTAPGGT1BFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713469-A1 METHOD OF REDUCING EMULSION FORMATIONDURING FERMENTATION PROCESS DSM IP Assets B.V. (NL) 2026-03-25 EP disclosed
US-20260071239-A1 COMPOSITIONS AND METHODS FOR IMPROVED CELL CULTURE EFFICIENCY AMYRIS INC (US) 2026-03-12 US disclosed
EP-2217711-B2 PRODUCTION OF ISOPRENOIDS AMYRIS INC (US) 2025-04-23 EP disclosed
US-20250122551-A1 PRODUCTION OF ISOPRENOIDS EUAGORE, LLC 2025-04-17 US disclosed
EP-4536615-A1 COMPOSITIONS AND METHODS FOR IMPROVED CELL CULTURE EFFICIENCY Amyris, Inc. (US) 2025-04-16 EP disclosed
WO-2024235968-A1 METHOD OF REDUCING EMULSION FORMATIONDURING FERMENTATION PROCESS DSM IP ASSETS B.V. (NL) 2024-11-21 WO disclosed
US-12146176-B2 Production of isoprenoids Amyris, Inc. (US) 2024-11-19 US disclosed
EP-3665292-B1 PROCESS FOR RECOVERING ISOPRENOIDS PRODUCED BY MICROORGANISMS TOTAL RAFFINAGE CHIMIE (FR) 2024-03-06 EP disclosed
US-20240035061-A1 PRODUCTION OF ISOPRENOIDS EUAGORE, LLC 2024-02-01 US disclosed
WO-2023239939-A1 COMPOSITIONS AND METHODS FOR IMPROVED CELL CULTURE EFFICIENCY Amyris, Inc. (US) 2023-12-14 WO disclosed
US-7659097-B2 Production of isoprenoids AMYRIS BIOTECHNOLOGIES, INC. (US) 2010-02-09 US disclosed
US-20090203019-A1 Methods of Monitoring Metabolic Pathways EUAGORE, LLC 2009-08-13 US disclosed
WO-2009097339-A1 METHODS OF MONITORING METABOLIC PATHWAYS AMYRIS BIOTECHNOLOGIES, INC. (US) 2009-08-06 WO disclosed
CN-101484584-A Production of isoprenoids AMYRIS BIOTECHNOLOGIES INC (US) 2009-07-15 CN disclosed
US-20090137014-A1 PRODUCTION OF ISOPRENOIDS EUAGORE, LLC 2009-05-28 US disclosed
WO-2009042070-A2 PRODUCTION OF ISOPRENOIDS AMYRIS BIOTECHNOLOGIES, INC. (US) 2009-04-02 WO disclosed
EP-2024504-A2 PRODUCTION OF ISOPRENOIDS Amyris Biotechnologies, Inc. (US) 2009-02-18 EP disclosed
US-20080274523-A1 PRODUCTION OF ISOPRENOIDS EUAGORE, LLC 2008-11-06 US disclosed
WO-2008128159-A1 PRODUCTION OF ISOPRENOIDS AMYRIS BIOTECHNOLOGIES, INC. (US) 2008-10-23 WO disclosed
WO-2007140339-A2 PRODUCTION OF ISOPRENOIDS AMYRIS BIOTECHNOLOGIES, INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260071239-A1 COMPOSITIONS AND METHODS FOR IMPROVED CELL CULTURE EFFICIENCY RHOA, NFATC1, CYP46A1 BTN3A1 4489/4885MVD 998/4885FNTA 28/4885
US-20090203019-A1 Methods of Monitoring Metabolic Pathways COASY, FDPS, GGPS1 BTN3A1 4860/4885MVD 227/4885FNTA 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.